Drug Approval | December 20, 2022
Imfinzi plus Imjudo recommended for approval in the EU by CHMP for advanced liver and lung cancers
Positive opinions based on significant survival benefit
Positive opinions based on significant survival benefit
Approval based on HIMALAYA Phase III trial results which showed single priming dose of Imjudo added to Imfinzi reduced risk of death by 22% vs. sorafenib
These results will be presented on 21 January at the 2022 American Society of Clinical Oncology (ASCO) Gastrointestinal Cancers Symposium
The trial met the primary endpoint of overall survival with a single priming dose of tremelimumab plus Imfinzi every four weeks vs. sorafenib
The CASPIAN Phase III trial in extensive-stage small-cell lung cancer is the longest survival follow-up ever reported for immunotherapy treatment in this setting
Tremelimumab (Imjudo) in combination with Durvalumab (Imfinzi) is indicated for the treatment of patients with unresectable hepatocellular carcinoma
Presidential Symposium for NIAGARA will highlight practice-changing impact of a perioperative Imfinzi-based regimen in bladder cancer
Back-to-back plenary presentations for LAURA and ADRIATIC Phase III trials reinforce the potential of Tagrisso and Imfinzi in early lung cancer settings
Very strong revenue and EPS growth in the first quarter coupled with exciting pipeline delivery
The British-Swedish pharma major certainly has a strong competitive edge for BTC treatment in the country
Subscribe To Our Newsletter & Stay Updated
